人工血管CIRCULINE■在血透通路中的应用:单中心结果

he clinical application experience of CIRCULINE■artificial vascular graft in vascular access:A single-center experience

目的总结CIRCULINE■人工血管在血透通路中的单中心临床应用经验。方法回顾性分析2020年11月至2022年6月上海中医药大学附属龙华医院47例使用CIRCULINE■人工血管建立动静脉内瘘的患者临床应用情况。结果手术成功率100%。人工血管动静脉内瘘均成功穿刺使用,首次穿刺时间为术后22~542 d,平均(56±76)d。患者随访率100%,平均随访时间(654±220)d。随访期间10例患者死亡,死亡前通路均通畅;共发生35例狭窄,20例血栓,6例感染,5例襻底打折,均行相应处理,无夹层发生。患者术后6、12、24个月的初级通畅率分别为74.5%、44.7%、27.7%,次级通畅率分别为97.9%、97.9%、93.6%。结论使用CIRCULINE■人工血管作为血液透析通路是安全可行的。

Objective To summarize the single-center clinical application experience of CIRCULINE■artificial vascular graft in vascular access.Methods The clinical application of 47 cases of CIRCULINE■vascular graft established at Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from November 2020 to June 2022 were retrospectively analyzed.Results The surgical success rate was 100%.All artificial arteriovenous fistulas were successfully punctured and used for dialysis access,with a mean time from surgery to first puncture ranging from 22 to 542 days and an average time of(56±76)days.The follow-up rate was 100%,with an average follow-up period of(654±220)days.10 cases died during the follow-up period,all vascular access were unobstructed before death.There were a total of 34 cases with stenosis,20 cases with thrombosis,6 cases with infection,5 cases with cannula fracture requiring corresponding treatment,and no dissection occurred.The primary patency rates at 6,12,and 24 months were 74.5%,44.7%,and 27.7%,respectively,and the secondary patency rates were 97.9%,97.9%,and 93.6%,respectively.Conclusion CIRCULINE■artificial vascular graft is safe and feasible as vascular access in hemodialysis patients.